Hide metadata

dc.date.accessioned2020-03-12T19:18:30Z
dc.date.available2020-03-12T19:18:30Z
dc.date.created2019-05-20T20:10:43Z
dc.date.issued2019
dc.identifier.citationBorgen, Tove Tveitan Bjørnerem, Åshild Solberg, Lene Bergendal Andreasen, Camilla Brunborg, Cathrine Stenbro, May-Britt Hübschle, Lars Michael Froholdt, Anne Figved, Wender Apalset, Ellen M Gjertsen, Jan-Erik Basso, Trude Lund, Ida Hansen, Ann Kristin Stutzer, Jens-Meinhard Dahl, Cecilie Omsland, Tone Kristin Nordsletten, Lars Frihagen, Frede Jon Eriksen, Erik Fink . High prevalence of vertebral fractures and low trabecular bone score in patients with fragility fractures: A cross-sectional sub-study of NoFRACT. Bone. 2019, 122, 14-21
dc.identifier.urihttp://hdl.handle.net/10852/73967
dc.description.abstractPurpose Norway has among the highest incidence rates of fractures in the world. Vertebral fracture assessment (VFA) and trabecular bone score (TBS) provide information about fracture risk, but their importance have not been studied in Norwegian patients with fragility fractures. The objectives of this study were to examine the clinical characteristics of a cohort of women and men with fragility fractures, their prevalence of vertebral fractures using VFA and prevalence of low TBS, and explore the differences between the sexes and patients with and without vertebral fractures. Methods This cross-sectional sub-study of the Norwegian Capture the Fracture Initiative (NoFRACT) included 839 patients with fragility fractures. Of these, 804 patients had bone mineral density (BMD) of the total hip, femoral neck and/or spine assessed using dual energy x-ray absorptiometry, 679 underwent concomitant VFA, 771 had TBS calculated and 696 responded to a questionnaire. Results Mean age was 65.8 (SD 8.8) years and 80.5% were women. VFA revealed vertebral fractures in 34.8% of the patients and 34.0% had low TBS (≤ 1.23), with no differences between the sexes. In all patients with valid measures of both VFA and TBS, 53.8% had either vertebral fractures, low TBS, or both. In the patients with osteopenia at the femoral neck, 53.6% had either vertebral fractures, low TBS, or both. Femoral neck BMD T-score ≤ −2.5 was found in 13.8% of all patients, whereas the corresponding figure was 27.4% using the skeletal site with lowest T-score. Women exhibited lower BMD at all sites and lower TBS than men (1.27 vs. 1.29), (all p < 0.05). Patients with prevalent vertebral fractures were older (69.4 vs. 64.0 years), exhibited lower BMD at all sites and lower TBS (1.25 vs.1.29) than those without vertebral fractures (all p < 0.05). Before assessment, 8.2% were taking anti-osteoporotic drugs (AOD), and after assessment, the prescription rate increased to 56.2%. Conclusions More than half of the patients with fragility fractures had vertebral fractures, low TBS or both. The prescription of AOD increased seven fold from before assessment to after assessment, emphasizing the importance of risk assessment after a fragility fracture.
dc.languageEN
dc.publisherElsevier Science
dc.relation.ispartofBorgen, Tove Tveitan (20209 Trabecular bone score and vertebral fracture assessment in patients with fragility fractures. Doctoral thesis http://hdl.handle.net/10852/76580
dc.relation.urihttp://hdl.handle.net/10852/76580
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titleHigh prevalence of vertebral fractures and low trabecular bone score in patients with fragility fractures: A cross-sectional sub-study of NoFRACT
dc.typeJournal article
dc.creator.authorBorgen, Tove Tveitan
dc.creator.authorBjørnerem, Åshild
dc.creator.authorSolberg, Lene Bergendal
dc.creator.authorAndreasen, Camilla
dc.creator.authorBrunborg, Cathrine
dc.creator.authorStenbro, May-Britt
dc.creator.authorHübschle, Lars Michael
dc.creator.authorFroholdt, Anne
dc.creator.authorFigved, Wender
dc.creator.authorApalset, Ellen M
dc.creator.authorGjertsen, Jan-Erik
dc.creator.authorBasso, Trude
dc.creator.authorLund, Ida
dc.creator.authorHansen, Ann Kristin
dc.creator.authorStutzer, Jens-Meinhard
dc.creator.authorDahl, Cecilie
dc.creator.authorOmsland, Tone Kristin
dc.creator.authorNordsletten, Lars
dc.creator.authorFrihagen, Frede Jon
dc.creator.authorEriksen, Erik Fink
cristin.unitcode185,53,11,16
cristin.unitnameAvdeling for endokrinologi, sykelig overvekt og forebyggende medisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin1698932
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Bone&rft.volume=122&rft.spage=14&rft.date=2019
dc.identifier.jtitleBone
dc.identifier.volume122
dc.identifier.startpage14
dc.identifier.endpage21
dc.identifier.doihttps://doi.org/10.1016/j.bone.2019.02.008
dc.identifier.urnURN:NBN:no-77094
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn8756-3282
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/73967/4/1-s2.0-S8756328219300481-main.pdf
dc.type.versionPublishedVersion


Files in this item

Appears in the following Collection

Hide metadata

Attribution-NonCommercial-NoDerivatives 4.0 International
This item's license is: Attribution-NonCommercial-NoDerivatives 4.0 International